Clear Harbor Asset Management LLC Sells 2,500 Shares of uniQure (NASDAQ:QURE)

Clear Harbor Asset Management LLC cut its holdings in shares of uniQure (NASDAQ:QURE) by 12.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 17,000 shares of the biotechnology company’s stock after selling 2,500 shares during the period. Clear Harbor Asset Management LLC’s holdings in uniQure were worth $300,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. American Century Companies Inc. boosted its stake in shares of uniQure by 14.6% in the 2nd quarter. American Century Companies Inc. now owns 67,699 shares of the biotechnology company’s stock valued at $303,000 after purchasing an additional 8,642 shares in the last quarter. Vanguard Personalized Indexing Management LLC boosted its position in uniQure by 21.0% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 2,306 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of uniQure during the second quarter worth $175,000. Cubist Systematic Strategies LLC increased its holdings in shares of uniQure by 130.9% during the second quarter. Cubist Systematic Strategies LLC now owns 25,494 shares of the biotechnology company’s stock worth $114,000 after buying an additional 14,454 shares in the last quarter. Finally, Algert Global LLC bought a new position in shares of uniQure in the 2nd quarter valued at $176,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on QURE. Leerink Partners boosted their price objective on uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 11th. Wells Fargo & Company upgraded uniQure from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 10th. Royal Bank of Canada reiterated an “outperform” rating and set a $24.00 target price on shares of uniQure in a research report on Tuesday. Mizuho boosted their target price on shares of uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 19th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of uniQure in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $34.38.

Insider Buying and Selling at uniQure

In related news, CEO Matthew C. Kapusta sold 3,418 shares of the company’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $7.63, for a total value of $26,079.34. Following the sale, the chief executive officer now owns 597,915 shares in the company, valued at $4,562,091.45. This represents a 0.57 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 4.74% of the company’s stock.

uniQure Stock Performance

Shares of uniQure stock opened at $15.29 on Thursday. The business has a 50-day moving average price of $12.39 and a two-hundred day moving average price of $8.56. uniQure has a 1-year low of $3.73 and a 1-year high of $19.18. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The company has a market cap of $745.23 million, a P/E ratio of -3.08 and a beta of 0.41.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, beating the consensus estimate of ($1.12) by $0.21. The company had revenue of $2.29 million during the quarter, compared to analyst estimates of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. As a group, analysts anticipate that uniQure will post -3.74 EPS for the current year.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.